Exelixis, Inc. $EXEL Shares Sold by Systematic Financial Management LP

Systematic Financial Management LP lessened its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 28.2% in the first quarter, Holdings Channel.com reports. The institutional investor owned 709,127 shares of the biotechnology company’s stock after selling 278,183 shares during the quarter. Systematic Financial Management LP’s holdings in Exelixis were worth $30,415,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also modified their holdings of EXEL. Wealth Enhancement Advisory Services LLC grew its stake in shares of Exelixis by 62.5% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 187,154 shares of the biotechnology company’s stock worth $8,224,000 after purchasing an additional 71,987 shares during the last quarter. Stephens Investment Management Group LLC raised its position in Exelixis by 1.1% during the 4th quarter. Stephens Investment Management Group LLC now owns 2,539,421 shares of the biotechnology company’s stock valued at $111,303,000 after purchasing an additional 28,265 shares during the last quarter. Nisa Investment Advisors LLC lifted its holdings in Exelixis by 692.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 140,446 shares of the biotechnology company’s stock worth $6,156,000 after buying an additional 122,720 shares during the period. SG Americas Securities LLC lifted its holdings in Exelixis by 72.1% in the 4th quarter. SG Americas Securities LLC now owns 36,288 shares of the biotechnology company’s stock worth $1,591,000 after buying an additional 15,203 shares during the period. Finally, Allspring Global Investments Holdings LLC grew its position in shares of Exelixis by 18.5% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,383,820 shares of the biotechnology company’s stock worth $60,307,000 after buying an additional 216,048 shares during the last quarter. Institutional investors own 85.27% of the company’s stock.

Insider Buying and Selling

In other Exelixis news, EVP Dana Aftab sold 43,451 shares of the stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $50.35, for a total value of $2,187,757.85. Following the completion of the transaction, the executive vice president owned 594,741 shares in the company, valued at approximately $29,945,209.35. This represents a 6.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Christopher J. Senner sold 34,901 shares of the firm’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $50.00, for a total value of $1,745,050.00. Following the transaction, the chief financial officer directly owned 952,317 shares of the company’s stock, valued at $47,615,850. This represents a 3.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 219,170 shares of company stock valued at $10,620,641 over the last 90 days. 2.60% of the stock is currently owned by company insiders.

Exelixis Stock Performance

Exelixis stock opened at $55.65 on Friday. Exelixis, Inc. has a fifty-two week low of $33.76 and a fifty-two week high of $57.57. The stock’s 50 day simple moving average is $53.06 and its two-hundred day simple moving average is $47.13. The stock has a market cap of $13.99 billion, a price-to-earnings ratio of 18.49, a PEG ratio of 1.58 and a beta of 0.42.

Exelixis (NASDAQ:EXEL) last announced its earnings results on Tuesday, May 5th. The biotechnology company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.75 by $0.12. The firm had revenue of $610.81 million during the quarter, compared to analyst estimates of $607.51 million. Exelixis had a return on equity of 39.89% and a net margin of 35.08%.The business’s revenue was up 10.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.55 EPS. On average, analysts predict that Exelixis, Inc. will post 3.16 earnings per share for the current year.

Analyst Ratings Changes

EXEL has been the topic of several research analyst reports. Royal Bank Of Canada boosted their target price on Exelixis from $43.00 to $46.00 and gave the company a “sector perform” rating in a research note on Tuesday, July 7th. HC Wainwright reaffirmed a “buy” rating and issued a $56.00 price target on shares of Exelixis in a research note on Thursday, July 2nd. Citigroup reiterated a “market outperform” rating on shares of Exelixis in a report on Wednesday. Stifel Nicolaus boosted their price objective on shares of Exelixis from $44.00 to $47.00 and gave the company a “hold” rating in a research report on Wednesday, May 6th. Finally, Weiss Ratings upgraded shares of Exelixis from a “buy (b)” rating to a “buy (b+)” rating in a report on Wednesday, July 8th. Nine research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $49.00.

Exelixis Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.